
Health • Diseases
Health Canada Approves DAWNZERA for Hereditary Angioedema Attack Prevention
CELYSTRA Pharma announced that Health Canada has approved DAWNZERA for preventing hereditary angioedema attacks in patients aged 12 and older, adding a new RNA targeted treatment option for Canadians living with this rare genetic disorder and its unpredictable swelling episodes.




